GlycoMimetics Company Profile (NASDAQ:GLYC)

About GlycoMimetics

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLYC
  • CUSIP:
Key Metrics:
  • Previous Close: $6.36
  • 50 Day Moving Average: $6.12
  • 200 Day Moving Average: $6.56
  • 52-Week Range: $4.28 - $9.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.40
  • P/E Growth: 0.00
  • Market Cap: $146.69M
  • Outstanding Shares: 23,065,000
  • Beta: 2.97
  • Return on Equity: -78.05%
  • Return on Assets: -67.09%
  • Current Ratio: 8.60%
  • Quick Ratio: 8.60%
Additional Links:
Companies Related to GlycoMimetics:

Analyst Ratings

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.50 (112.26% upside)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
DateFirmActionRatingPrice TargetDetails
12/6/2016Canaccord GenuitySet Price TargetBuy$12.00View Rating Details
11/30/2016SunTrust Banks, Inc.Reiterated RatingBuyView Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$13.00 -> $15.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for GlycoMimetics (NASDAQ:GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017($0.35)N/AView Earnings Details
11/4/2016Q216($0.44)($0.34)ViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
8/6/2015($0.40)$0.51ViewN/AView Earnings Details
3/16/2015($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014($0.08)$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/9/2014Q114($0.29)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.46)($0.38)($0.42)
Q3 20162($0.54)($0.36)($0.45)
Q4 20162($0.55)($0.37)($0.46)
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)


Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for GlycoMimetics (NASDAQ:GLYC)
Insider Ownership Percentage: 52.50%
Institutional Ownership Percentage: 79.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
News IconMd. drug pricing transparency bill misunderstands U.S. medicine market (NASDAQ:GLYC) - February 22 at 5:42 PM logoForm SC 13G/A GLYCOMIMETICS INC Filed by: FRANKLIN RESOURCES INC (NASDAQ:GLYC) - February 8 at 6:02 PM logo3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban (NASDAQ:GLYC) - February 8 at 6:02 PM logoBidding War For Galectin Inhibitors May Heat Up With GTCBio Conference (NASDAQ:GLYC) - February 6 at 5:31 PM logoGreater Washington's fastest-growing company forced to lower earnings, income for two years (NASDAQ:GLYC) - January 24 at 6:08 PM
News IconGlycoMimetics Inc GLYC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:GLYC) - January 15 at 3:33 AM logo10:04 am GlycoMimetics announces results of its Phase 1/2 clinical trial on GMI-1271 continue to show 'high rates of remission' and 'favorable' tolerability among study participants with acute myeloid leukemia; data shared at the 58yh Ameri (NASDAQ:GLYC) - December 5 at 6:02 PM logoGlycoMimetics (GLYC) Announces Positive Update on GMI-1271 Phase 1/2 in AML; All Response Patients Seen with CR Rates (NASDAQ:GLYC) - December 5 at 11:21 AM logoGlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML (NASDAQ:GLYC) - December 5 at 11:21 AM logoGlycoMimetics to Present at Upcoming Healthcare Investor Conferences (NASDAQ:GLYC) - November 10 at 4:35 PM logoGlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting (NASDAQ:GLYC) - November 8 at 4:34 PM logoGlycoMimetics, Inc. (NASDAQ:GLYC) Files An 8-K Reports Third Quarter 2016 Results And Progress In Clinical Development (NASDAQ:GLYC) - November 4 at 4:09 PM logoGlycoMimetics reports 3Q loss (NASDAQ:GLYC) - November 4 at 4:09 PM logoGLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit (NASDAQ:GLYC) - November 4 at 4:09 PM logoGlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development (NASDAQ:GLYC) - November 4 at 4:09 PM logoData from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of Hematology (ASH) Meeting (NASDAQ:GLYC) - November 3 at 4:56 PM logo9:36 am GlycoMimetics will present data from 3 drug candidates at ASH (NASDAQ:GLYC) - November 3 at 4:56 PM logoGalectin 3 Pipeline Review, H2 2016: 5 Companies & 14 Molecules - Research and Markets (NASDAQ:GLYC) - October 12 at 10:17 AM logoGLYCOMIMETICS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:GLYC) - September 23 at 10:13 AM logoForm 8-K GLYCOMIMETICS INC For: Sep 20 (NASDAQ:GLYC) - September 23 at 10:13 AM logoGLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:GLYC) - September 23 at 10:13 AM logoGlycoMimetics : Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 (NASDAQ:GLYC) - September 15 at 5:38 PM logoBRIEF-Twitter launches new app for Apple tv, Amazon Fire tv, Xbox (NASDAQ:GLYC) - September 15 at 8:19 AM logoGlycoMimetics (GLYC) Announces Dosing of First Patient in GMI-1271 Phase 1 for Multiple Myeloma (NASDAQ:GLYC) - September 15 at 8:19 AM logoGlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma (NASDAQ:GLYC) - September 14 at 9:30 AM logoGlycomimetics : Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care (NASDAQ:GLYC) - September 9 at 5:03 PM logoGlycomimetics Joins New Sickle Cell Disease Coalition, Issues Call to Action to Improve Treatment and Care (NASDAQ:GLYC) - September 9 at 5:03 PM logoGlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 (NASDAQ:GLYC) - September 6 at 9:59 AM
News IconLatest report 2016 H2 thromboembolism pipeline market key companies analysis research (NASDAQ:GLYC) - September 2 at 10:06 AM logoBRIEF-GlycoMimetics announces publication of preclinical data (NASDAQ:GLYC) - August 17 at 5:27 PM
News IconLeukemia Drug Shows Potential as Heart Attack Therapy (NASDAQ:GLYC) - August 17 at 5:27 PM logoGlycoMimetics (GLYC) Announces Publication of Positive GMI-1271 Data in Post-Heart Attack Inflammatory Response Reduction (NASDAQ:GLYC) - August 17 at 5:27 PM logoGlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack (NASDAQ:GLYC) - August 16 at 5:24 PM logoGlycoMimetics Initiated At Outperform By Cowen And Company (NASDAQ:GLYC) - August 15 at 5:26 PM logoGLYCOMIMETICS INC Financials (NASDAQ:GLYC) - August 12 at 5:18 PM logoGlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference (NASDAQ:GLYC) - August 8 at 10:01 AM logoGlycoMimetics reports 2Q loss (NASDAQ:GLYC) - August 5 at 8:10 AM logoGlycoMimetics Reports Second Quarter 2016 Results (NASDAQ:GLYC) - August 4 at 5:34 PM logoManufacturing Stocks Top Losers, Gainers (NASDAQ:GLYC) - July 27 at 5:04 AM logoCoverage initiated on GlycoMimetics by SunTrust (NASDAQ:GLYC) - July 26 at 7:34 AM logoGlycoMimetics : Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia (NASDAQ:GLYC) - July 8 at 8:05 AM logoWarp Drive Bio Appoints Rachel K. King to Its Board of Directors (NASDAQ:GLYC) - July 5 at 9:56 AM logoGlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia (NASDAQ:GLYC) - June 28 at 9:11 AM logoGlycoMimetics (GLYC) Prices 3.3M Common Stock Offering at $6.10/Share (NASDAQ:GLYC) - June 18 at 4:50 PM logoGLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements (NASDAQ:GLYC) - June 17 at 4:13 PM logo5 Biggest Mid-Day Losers For Friday (NASDAQ:GLYC) - June 17 at 2:18 PM logoGlycoMimetics Announces Pricing of Public Offering of Common Stock (NASDAQ:GLYC) - June 17 at 10:19 AM logoGlycoMimetics Announces Proposed Public Offering of Common Stock (NASDAQ:GLYC) - June 16 at 4:49 PM
News IconGlycoMimetics' GMI-1271 receives US FDA Fast Track status for acute myeloid leukemia treatment (NASDAQ:GLYC) - June 15 at 9:54 AM logoGlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia (NASDAQ:GLYC) - June 14 at 10:01 AM


What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

5 brokerages have issued 12 month target prices for GlycoMimetics' stock. Their forecasts range from $11.00 to $16.00. On average, they expect GlycoMimetics' stock price to reach $13.50 in the next year.

When will GlycoMimetics announce their earnings?

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (1/17/2017)

  • Cowen and Company analysts commented, "We also think wholly owned GMI-1271 has generated very promising Ph1/2 data in AML showing chemo potentiation and likely improved response rates to standard of care; followup data from more patients is due 4Q16," analyst Ritu Baral wrote in a note.Glycomimetics' clinical pipeline is currently focused on a class of cell-adhesion molecules called selectins that are central to bone marrow and blood cell adhesion.Related Link: GlycoMimetics Reports Dosing Of First Patient In Phase 2 Trial Of GMI-1271 In Newly Diagnosed AMLBaral continued that these molecules are key to interactions between stem and blood cells and vasculature/bone marrow structural tissues. These selectin antagonists prevent interactions by competitive binding, thereby potentially preventing certain disease-related processes.Rivipansel is currently in a late stage study in Sickle Cell Disease Vaso-Occlusive Crises (SCD VOC) with top-line data due in 2018, and the analyst believes the drug will see almost universal use in SCD crises in the United States with little to no contraindications."As such, we model a per treatment course of $10,000 and model relatively rapid uptake with peak sales of $1 billion in 2023 in US and EU. GLYC will receive low double digit royalties from PFE," (8/15/2016)

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (4.34%), Wall Street Associates (0.65%), State Street Corp (0.58%), Renaissance Technologies LLC (0.51%) and Russell Investments Group Ltd. (0.12%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Franklin Resources Inc..

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and State Street Corp. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlycoMimetics stock cost?

One share of GlycoMimetics stock can currently be purchased for approximately $6.36.

GlycoMimetics (NASDAQ:GLYC) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Earnings History Chart

Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)

Dividend History Chart

Dividend Payments by Quarter for GlycoMimetics (NASDAQ:GLYC)

Last Updated on 2/24/2017 by Staff